Tilt table for ergometers and other biomedical devices

Table adjusts to any position between horizontal and vertical. Apparatus includes - floor plate, plate hinged to floor plate, for carrying ergometer, hydraulic cylinder and piston on plate sides, linking them, hydraulic system, positive stops, padded backrest and headrest, one hand controls, and constraint system

Restraint system for ergometer

A restraint system for securing a person to an ergometer while exercising under zero gravity conditions or while operating the ergometer in earth environment in a position other than the upright position. A padded, form-fitting body belt fits around the operator's waist and suspenders are attached to the body belt. The body belt is secured to the ergometer forwardly and rearwardly of the ergometer seat by adjustable belts joined to the body belt and releasably hooked to the ergometer frame

Looking Ahead

[Excerpt] The American entertainment industry and its system of labor-management relations is now at a crossroads. Its future will be determined to a great extent by emerging developments that could either hinder or facilitate expansion, depending on the course of affairs approaching the year 2000. The key trends will converge to influence the course of collective bargaining in the industry and the choices made by unions and employers

Tilting table for ergometer and for other biomedical devices

The apparatus is for testing the human body in a variety of positions, ranging from the vertical to the supine, while exercising on an ergometer; and can also be used for angular positioning of other biomedical devices. It includes a floor plate and a hinged plate upon which to fix the ergometer, a back rest and a head rest attached at right angles to said hinged plate and behind the seat of the ergometer, dual hydraulic cylinders for raising and lowering the hinged plate through 90 deg by means of a self contained hydraulic system, with valve means for control and positive stops on the apparatus to prevent over travel. Tests can be made with the subject positioned on the seat of the ergometer, through the various angles, with a substantially normal body attitude relative to the seat and ergometer

The Industry and the Unions: An Overview

[Excerpt] This overview chapter provides a framework for the chapters that follow by broadly describing the arts, entertainment, and electronic media (AEEM) industry and the problems confronting it. The overview is presented in four sections focused on: first, the economic structure of the industry; second, unions and bargaining structure; third, the impact of technological changes; and fourth, historical responses on the part of unions and the labor relations system to technological change

Multimode ergometer system

System overcomes previous ergometer design and calibration problems including inaccurate measurements, large weight, size, and input power requirements, poor heat dissipation, high flammability, and inaccurate calibration. Device consists of lightweight, accurately controlled ergometer, restraint system, and calibration system

Manufacturer Liability for Harms Caused by Consumers to Others

Should the manufacturer of a product be held legally responsible when a consumer, while using the product, harms someone else? We show that if consumers have deep pockets, then manufacturer liability is not desirable. If homogeneous consumers have limited assets, then the best rule is "residual-manufacturer liability" where the manufacturer pays the shortfall in damages not paid by the consumer. Residual-manufacturer liability distorts the market quantity when consumers' willingness to pay is correlated with their propensity to cause harm. It distorts product safety when consumers differ in their wealth levels. In both cases, consumer-only liability may be preferred

Manufacturer Liability for Harms Caused by Consumers to Others

This paper investigates whether manufacturers should be liable if consumers, through the use of a product, cause harm to others. If consumers have deep pockets then consumer-only liability is socially desirable. With consumer insolvency, however, consumer-only liability leads to inadequate consumer precautions, inadequate safety features, and excessive economic activity. With homogeneous insolvent consumers, the best rule is residual-manufacturer liability where the consumer bears primary responsibility and the manufacturer bears the shortfall in damages. When consumers\u27 willingness-to-pay is correlated with social harm they cause then residual-manufacturer liability distorts the market quantity. When consumers differ in their wealth then residual-manufacturer liability creates an inefficient cross-subsidization and an overprovision of safety features. In both cases, consumer-only liability may be preferred to residual-manufacturer liability. Applications, including gun manufacturer liability, are discussed

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described. Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF. Animals: Three hundred and fifty-four dogs with MMVD and cardiomegaly. Materials and Methods: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4-0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points (day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic variables and time to CHF or CRD were explored. Results: At day 35, heart size had reduced in the pimobendan group:median change in (Delta) LVIDDN -0.06 (IQR:-0.15 to + 0.02), P < 0.0001, and LA:Ao -0.08 (IQR:-0.23 to + 0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD. Hazard ratio for a 0.1 increase in Delta LVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1 increase in Delta LA:Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar. Conclusions and Clinical Importance: Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo

Genome Sequence of Corynebacterium pseudotuberculosis MB20 bv. equi Isolated from a Pectoral Abscess of an Oldenburg Horse in California.

The genome of Corynebacterium pseudotuberculosis MB20 bv. equi was sequenced using the Ion Personal Genome Machine (PGM) platform, and showed a size of 2,363,089 bp, with 2,365 coding sequences and a GC content of 52.1%. These results will serve as a basis for further studies on the pathogenicity of C. pseudotuberculosis bv. equi